CompletedPhase 2

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

United Kingdom48 participantsStarted 2008-05

Plain-language summary

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with congenital idiopathic nystagmus or acquired nystagmus subsequent to multiple sclerosis * male or female outpatients * aged between 18 and 80 years (inclusive) at screening Exclusion Criteria: * patients with evidence of neurologic disorders other than CIN such as congenital nystagmus due to albinism or retinal diseases and/or acquired nystagmus (exemption: secondary to MS)

What they're measuring

Visual acuity

Timeframe: Screening, Baseline, Week 3, 7, 11, 14, 18, and Follow-up

Trial details

NCT IDNCT00661440

SponsorMerz Pharmaceuticals GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Nystagmus, Congenital Idiopathic trials